Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 25, 2025Open Access

Efficacy and safety of Ocrelizumab in comparison to placebo for multiple sclerosis: A systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

ANAsif NawazFoundation University Medical CollegeABArsalan BakhtiyarKhyber Medical CollegeEKEshan KhanAllegheny Health Network

Discussion

Loading...

Member takes

Overview

Meta-analysis shows ocrelizumab reduces relapse rates in multiple sclerosis, suggesting potential benefits over placebo.

Key Points

  • Ocrelizumab effectively reduces annualized relapse rate (ARR) in multiple sclerosis patients, with significant findings.
  • A combined risk ratio of 0.54 indicates ocrelizumab reduces relapses compared to placebo in 24 studies.
  • Systematic review combined 5 RCTs and 19 observational studies employing Newcastle–Ottawa Scale for bias assessment.
  • Ocrelizumab's safety profile is similar to placebo, yet monitoring for long-term effects remains essential.

Cite This Study

Nawaz et al. (2025) studied this question.

synapsesocial.com/papers/68af5f07ad7bf08b1eae1868https://doi.org/10.21203/rs.3.rs-7114838/v1
View Full Paper
Ask AI
Bookmark
Share